Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Shares Outstanding (2016 - 2025)

Protalix BioTherapeutics has reported Shares Outstanding over the past 16 years, most recently at $80.4 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $80.4 million for Q4 2025, up 6.03% from a year ago — trailing twelve months through Dec 2025 was $80.4 million (up 6.03% YoY), and the annual figure for FY2025 was $80.4 million, up 6.03%.
  • Shares Outstanding for Q4 2025 was $80.4 million at Protalix BioTherapeutics, roughly flat from $80.3 million in the prior quarter.
  • Over the last five years, Shares Outstanding for PLX hit a ceiling of $80.4 million in Q4 2025 and a floor of $45.4 million in Q1 2021.
  • Median Shares Outstanding over the past 5 years was $72.3 million (2023), compared with a mean of $63.7 million.
  • Biggest five-year swings in Shares Outstanding: soared 46.94% in 2023 and later rose 0.93% in 2024.
  • Protalix BioTherapeutics' Shares Outstanding stood at $45.6 million in 2021, then increased by 18.07% to $53.8 million in 2022, then soared by 35.62% to $73.0 million in 2023, then rose by 3.97% to $75.9 million in 2024, then increased by 6.03% to $80.4 million in 2025.
  • The last three reported values for Shares Outstanding were $80.4 million (Q4 2025), $80.3 million (Q3 2025), and $79.7 million (Q2 2025) per Business Quant data.